Method for improvement of cellulite appearance

ABSTRACT

A method and apparatus are provided for treating connective tissue. The method and apparatus includes elongating connective tissue including septa and/or fascia to achieve a lasting improvement (e.g., a long term, durable and/or substantially irreversible treatment of the connective tissue) to improve the appearance of cellulite.

RELATED APPLICATIONS

The present application claims priority as a continuation to U.S. application Ser. No. 12/842,734 filed on Jul. 23, 2010, and entitled “Method for Improvement of Cellulite Appearance,” which claims priority to a provisional application filed on Jul. 23, 2009, and entitled “Method for Improvement of Cellulite Appearance” and having U.S. Ser. No. 61/271,593. Each of these applications are incorporated by reference in their entireties.

BACKGROUND OF THE INVENTION

The appearance of cellulite on a person's body can create a perception that the person is unfit and/or overweight. Individuals, generally women who have cellulite, often view it as unflattering and as a source of embarrassment. It is desirable to improve and/or eliminate the appearance of cellulite such that the appearance of cellulite is improved and/or eliminated in one or more locations of a subject's body for a relatively long period of time. It is most desirable to achieve a long term and/or durable improvement and/or to eliminate the appearance of cellulite in treated regions.

SUMMARY OF THE INVENTION

In accordance with the methods and devices disclosed herein the invention relates to the treatment of connective tissue in a subject's body to improve the appearance of cellulite on a subject's body. In some embodiments, the methods and devices treat connective tissue with substantially lasting, durable and/or irreversible results. Long lasting, durable and/or irreversible treatment of connective tissue can improve the appearance of cellulite for a relatively long period of time and/or substantially permanently.

In one aspect, the invention relates to a method of improving the appearance of cellulite and the method includes applying a stretching force to at least one of a septa tissue and a fascia tissue that is adjacent to fat tissue and is located beneath a region of a subject's skin having the appearance of cellulite. At least one of the septa tissue and the fascia tissue are heated for a period of time and at a temperature less than is required to fully coagulate any of the septa tissue, the fascia tissue and the fat tissue. In some embodiments, there is heating with no coagulation. After heating the length of at least one of the septa tissue and the fascia tissue is increased relative to the length of at least one of the septa tissue and the fascia tissue prior to applying the stretching force and/or the heating. The method can also include the step of removal of the stretching force. Improvement of the appearance of cellulite can be determined by visual inspection of the region of the subject's skin that is treated.

In another aspect, the invention relates to a method of improving the appearance of cellulite. The method includes applying a stretching force to at least one of a septa tissue and a fascia tissue that is adjacent to fat tissue and is beneath a region of a subject's skin having the appearance of cellulite. The method also includes heating at least one of the septa tissue and the fascia tissue for a period of time and at a temperature sufficient to achieve lasting elongation of at least one of the septa tissue and the fascia tissue upon release of the stretching force. In some embodiments, applying the stretching force and heating at least one of the septa tissue and the fascia tissue occur simultaneously. In other embodiments, heating of at least one of the septa tissue and the fascia tissue occurs in the presence of the previously applied stretching force.

In one embodiment, vacuum pressure applies the stretching force. Applying the stretching force can include inserting fluid into the subject's tissue. The fluid can be, for example, tumescent fluid or gas. Optionally, the fluid can be pre-heated such that the fluid itself provides heat at least one of the septa tissue and the fascia tissue. In another embodiment, one or more of radiofrequency energy, ultrasound energy, light energy, and microwave energy are employed to heat at least one of the septa tissue and the fascia tissue.

The method of improving the appearance of cellulite can further include employing a cannula to apply an energy source to heat at least one of the septa tissue and the fascia tissue. A suitable cannula can apply one or more of radiofrequency energy, ultrasound energy, light energy, and microwave energy to at least one of the septa tissue and the fascia tissue.

In one embodiment, heating includes bringing the temperature of at least one of the septa and the fascia to the temperature range from about 37° C. to about 60° C., or from about 40° C. to about 48° C. In accordance with methods of improving the appearance of cellulite, the increase in temperature of at least of the septa and the fascia can also heat the surrounding subcutaneous tissue (e.g., fat tissue) in the region of the targeted fascia and/or septa tissue.

In one embodiment, at least one of the septa tissue and the fascia tissue are heated for a period of time that ranges from about 10 seconds to about 60 minutes or from about 30 seconds to about 30 minutes. The method can also include cooling the external surface of the region of the subject's skin. The method can also include the step of removal of the stretching force.

Improvement of the appearance of cellulite can be determined by visual inspection of the region of the subject's skin that has been treated.

DESCRIPTION OF THE DRAWINGS

FIG. 1A is a schematic view of the inside of a female subject's body in a region of cellulite; the schematic view depicts the subcutaneous tissue, which is located between the skin (e.g., the epidermis and dermis) and muscle and bone. The subcutaneous tissue includes a relatively thin layer (e.g., a single layer) of subcutaneous fat.

FIG. 1B is a schematic view of the inside of a female subject's body of FIG. 1A where the region of tissue is stretched (by an external device or by the addition of tumescent fluid, which is injected inside the female subject's body) to increase the volume of the subcutaneous tissue region thereby enabling connective tissue (e.g., septa) in the subcutaneous tissue region to be stretched in a manner that is substantially lasting, durable and/or irreversible.

FIG. 1C is a schematic view of the inside of a female subject's body of FIG. 1B after the stretching force is removed (e.g., the external device is removed or the tumescent fluid is removed) and the connective tissue (e.g., septa) remains stretched in a manner that is substantially lasting, durable and/or irreversible.

FIG. 2A is a schematic view of the inside of a female subject's body in a region of cellulite; the schematic view depicts the subcutaneous tissue, which is located between the skin (e.g., the epidermis and dermis) and muscle and bone. The subcutaneous tissue includes a relatively thick layer (e.g., a multiple layers) of subcutaneous fat.

FIG. 2B is a schematic view of the inside of a female subject's body of FIG. 2A where the region of tissue is stretched (by an external device or by the addition of tumescent fluid, which is injected inside the female subject's body) to increase the volume of the subcutaneous tissue region thereby enabling connective tissue (e.g., septa and fascia) in the subcutaneous tissue region to be stretched in a manner that is substantially lasting, durable and/or irreversible.

FIG. 2C is a schematic view of the inside of a female subject's body of FIG. 2B after the stretching force is removed (e.g., the external device is removed or the tumescent fluid is removed) and the connective tissue (e.g., septa and fascia) remains stretched in a manner that is substantially lasting, durable and/or irreversible.

FIG. 3A shows a diagram of the generalized relationship of force applied to connective tissue on the x axis and the elongation of the connective tissue in response to the applied force on the y axis.

FIG. 3B shows a cellulite dimple under which fascia having a length L is located prior to elongation treatment.

FIG. 3C shows the improvement in the appearance of the cellulite dimple previously shown in FIG. 3B due to the elongation treatment of the fascia, after elongation treatment the fascia has a length of L+ΔLo.

FIG. 4 shows a device for externally heating subcutaneous tissue including septa and/or fascia, the device includes a first vacuum, one or more energy source(s), a cooling plate, and a second vacuum.

FIG. 5 shows a cross section of a device for externally heating a region of tissue, the device includes an energy source with adjacent cooling plate(s) and applies vacuum to the subcutaneous tissue including septa and/or fascia.

FIG. 6A shows a side view of a device having an outer housing which allows the recess in the device to accommodate varying tissue thicknesses (e.g., tissue fold thicknesses). The device features one or more energy source(s) and is adapted to apply vacuum pressure to the tissue region that is held within the device recess during treatment.

FIG. 6B shows a cross section of the device of FIG. 6A.

DETAILED DESCRIPTION

Anatomically, the cutaneous formation of cellulite is often due to fibrosis of the connective tissues present in the dermis and/or in the subcutaneous tissue. Connective tissue of the reticular dermis is connected to the deep fascia by fibrous septum from adipose or fat tissue. Subcutaneous fat lobules are separated from each other by fibrous septum (i.e., septa), which are generally relatively thin and usually rigid strands of connective tissue. The fibrous septa cross the fatty layer and connect the dermis to the underlying fascia tissue. The septa stabilize the subcutis and divide the fat tissue. Shortening of these septa due, for example, to fibrosis, causes retraction of the septa which in turn causes the depressions in the skin that are recognized as cellulite.

Thus, cellulite appears in the subcutaneous level of skin tissue where fat cells are arranged in chambers of fat tissue that are surrounded by bands of connective tissue called septae and/or fascia. Under certain conditions, for example, as water is retained, fat cells held within the perimeters of these fat tissue chambers expand and stretch the connective tissue. In some situations, the septa tissue is physiologically short and/or the septa tissue contracts and hardens holding the skin at a non-flexible length, while the surrounding tissue continues to expand with weight, or water gain, which results in areas of the skin being held down while other sections bulge outward, resulting in the lumpy, “cottage-cheese” appearance recognized as cellulite.

Referring now to FIG. 1A, inside a female subject's body 1000, between muscle 1009 and dermis 1008 is connective tissue called fiber stents or septa 1007. In some embodiments, bone 1013 is adjacent to muscle 1009. Fiber septa 1007 are bundles of connective tissue fibers that are held between the dermis 1008 and the muscle 1009. As discussed here, fiber stents include soft tissue such as fibrous septa, which is composed of collagen fiber material similar to what is found in the dermis tissue, vascular tissue, and lymph tissue. Septa 1007 align and connect the muscle 1009 and the dermis 1008 to one another. The septa 1007 traverse through at least a portion of fat tissue 1006 inside the subject's body 1002. In some subject's, generally in females, when a volume of fat tissue 1006 between septa 1007 (e.g., between one septae 1007 a and another septae 1007 b) is over a threshold amount it creates an uneven, dimpled, and/or bumpy appearance on the external portion of the body 1004 and these dimples 1003 and/or bumps in the tissue are recognized as cellulite appearance. Cellulite appears due to the interaction of the existing fat 1006 with the septa 1007. A person with low fat could have cellulite because they have tight septa 1007. In some instances, cutting the septa 1007 in the region of the dimples 1003 e.g., in the areas between the bumps with a knife to relieve the stress caused by the volume of fat tissue 1006 between septa 1007 (e.g., adjacent septa 1007 a and 1007 b) provides relief to the stress on the skin tissue that previously resulted in a dimpled and/or bumpy appearance. Cutting the septa 1007 can result in a flattening of the skin that was formerly bumpy in the region of the septa 1007. However, cutting the septa 1007 inside the skin is dangerous because it risks unintended consequences including nerve damage and muscle damage, for example.

Cellulite is generally a problem for females but is less common in males. In females the septa 1007 between the dermis 1008 and the muscle 1009 are substantially vertical relative to the plane of the dermis 1008 and/or the plane of the muscle 1009. Generally, the fibrous septa in women are orientated in a direction perpendicular to the cutaneous surface. In contrast, males have septa between the dermis and the muscle that are shifted to the side at an angle relative to the substantially vertical direction of the septa found in females. In males the septa have an angled or criss-cross pattern that does not feature the perpendicular direction relative to the cutaneous surface. Without being bound to a single theory, it is believed that the shifted angle of septa found in males provides a level of “give” that enables changes in fat quantity inside a male's body to not result in the cellulite appearance. In addition, subcutaneous fat is divided into lobules and in women the fat lobules are relatively larger and more rectangular when compared with the fat lobules found in men. The substantially vertical septa 1007 found in females does not afford the “give” provided by the criss-cross pattern in males, further, the relatively larger size of fat lobules in women contribute to the cellulite appearance problem being more common for females than for males.

Thus, the substantially vertically oriented septa 1007 in females are primarily responsible for the typical orange peel/bumpy appearance that is recognized as cellulite. FIG. 1A depicts body areas having relatively thin subcutaneous fat (e.g., a single layer of fat tissue 1006) such as, for example, the under arms and the abdomen (i.e., the belly). The relative thickness or thinness of a body area will vary depending on individual anatomy.

FIG. 2A like FIG. 1A shows a female subject's body 3000, more specifically, shows the inside 3002 of a female subject's body. FIG. 2A depicts a body area having a relatively thick layer of subcutaneous fat made up of multiple chambers of fat tissue (e.g., 3006 a, 3006 b, 3006 c, 3006 d, 3006 e, and 3006 f) some of which are stacked on one another (e.g., 3006 b and 3006 e). Relatively thick layers of subcutaneous fat that are made up of multiple chambers of fat tissue can include, for example, the buttocks and/or the thighs. The inside of a female subject's body 3000 under the epidermis 3010, between muscle 3009 and dermis 3008 includes connective tissues including septa 3007 (also referred to as fiber stents) and fascia 3011. In some embodiments body areas that include cellulite have bone 3013 adjacent to muscle 3009.

A woman's anatomy features connective tissue including one or more substantially vertical septa 3007; the substantially vertical septa 3007 are substantially vertical relative to at least one of the fascia 3011, the muscle 3009, and/or the skin (e.g., the epidermis 3010 and the dermis 3008). The septa 3007 traverse through at least a portion of fat tissue 3006 inside the subject's body 3002. Referring still to FIG. 2A in body areas having a relatively thick layer of subcutaneous fat, multiple layers of fat tissue 3006 are stacked between, above and below connective tissue. More specifically, inside the subject's body 3002 in the region of some body areas having a relatively thick region of subcutaneous fat, the fat tissue 3006 is stacked between substantially vertical septa 3007 and above and below substantially horizontal fascia 3011. In some embodiments, the fat tissue 3006 chambers (e.g., 3006 a, 3006 b, 3006 c, 3006 d, 3006 e, and 3006 f) have an irregular pattern.

The connective tissue including the septa 3007 and the fascia 3011 align and connect the muscle 3009 and the dermis 3008 to one another. In some subjects, generally in females, when a volume of fat tissue 3006 between connective tissue 3007 (e.g., between one septa 3007 b another septa (e.g., 3007 a and 3007 d) and fascia 3011) is over a threshold amount it creates an uneven, dimpled, and/or bumpy appearance on the external portion of the body 3004 and these dimples 3003 and/or bumps in the tissue are recognized as cellulite appearance. Cellulite appears due to the interaction of the existing fat 3006 with the connective tissue (e.g., the septa 3007 and/or the fascia 3011). Without being bound to any single theory it is believed that in some embodiments, the fascia 3011 connects to the septa 3007 and acts as an anchor that holds the septa 3007 in a position that increases the pull of the septa 3007 against the dermis 3008 and/or the epidermis 3010 and this tension/pull contributes to the cellulite appearance provided by the dimples 3003.

FIG. 3A is a diagram that shows the generalized relationship of force applied to connective tissue and the elongation of the connective tissue in response to the applied force. The force applied to connective tissue (e.g., septa and/or fascia) is shown on the x axis (force shown as F in arbitrary units (au)) and the y axis shows the elongation of the connective tissue (e.g., septa and/or fascia) as ΔL (in arbitrary units). The x axis also shows F_(el) which is the elasticity limit of the connective tissue being treated. The elasticity limit is the maximum force which provides a change in length ΔL of the connective tissue that is directly proportional to the applied force F. The x axis also shows F_(m), which is the maximum force applied during a given elongation treatment. The y axis shows ΔLo, which is the lasting elongation after releasing the force F applied to the connective tissue. Lasting elongation includes elongation that lasts for several hours after treatment, e.g., two or more hours after treatment and can include elongation that is substantially irreversible (i.e., elongation that is maintained and is substantially permanent) after treatment.

FIG. 3B shows a cellulite dimple 2003 under which septa 2007 having a length L is located prior to treatment. FIG. 3C shows the improvement in the appearance of the cellulite dimple previously shown in FIG. 3B due to the elongation treatment of the septa 2007. After the elongation treatment the septa 2007 in FIG. 3B has a length of (L+ΔLo).

As seen in FIG. 3A when the maximum force F_(m) is higher than the elasticity limit F_(el) then elongation of the connective tissue becomes non-linear such that it responds to the applied force that is greater than F_(el) in a non-linear manner. After releasing the applied force F the length of the connective tissue demonstrates hysteresis behavior as is shown in FIG. 3A, which results in the lasting elongation having the quantity depicted as ΔLo. The F_(el) can be a function of the tissue temperature and the time of application of the temperature to tissue. By elevating tissue temperature, the F_(el) may be lowered and the lasting elongation ΔLo can be achieved with the relatively lower Force than is required in the absence of an elevated temperature. Thus, by increasing the temperature of the connective tissue to be treated with a force F the amount of force required to improve the length of (e.g., elongate) the connective tissue is reduced. In this way, negative side effects to the body area being treated including tearing, bruising and pain can be reduced and/or avoided.

Without being bound to any single theory it is believed that similar improvement of the appearance of cellulite may be achieved by exposing at least one of the fascia and/or the septa to a relatively cold temperature (e.g., from about −5° C. to about 20° C., or from about 0° C. to about 10° C.) and a stretching force (applied simultaneous with or subsequent to exposure of the tissue to the cold temperature). This stretching force may be applied to the tissue for a time period that ranges from about 1 second to about 1 hour in order to achieve a lasting elongation of the septa and/or the fascia in order to a fracture the septa and/or the fascia, both elongation and fraction are believed to improve cellulite appearance. Cooling can be done externally by employing a cold plate with circulated water, a thermoelectric cooler, an ice pack or any other suitable external cooling means. Cooling may also be done internally by, for example, injecting cooled fluid into the treatment area (e.g., cooled tumescence or cooled water) or by inserting a cooled cannula to the treatment area.

In accordance with any method(s) or device(s) for elongating connective tissue disclosed herein, a chemical such as glycerol may be added to the connective tissue prior or during the elongation process. The chemical such as glycerol can enhance elasticity of the connective tissue to increase the amount of elongation achieved in accordance with the methods and devices disclosed herein.

Treatment of Subcutaneous Tissue by Stretching Connective Tissue

In one embodiment, referring now to FIG. 1A, the substantially vertical septa 1007 (also referred to as stents) that lie between the muscle 1009 and the dermis 1008 can be stretched in order to elongate the septa 1007 and to provide “give” to the septa 1007 that avoids and/or lessens the appearance of cellulite caused by substantially vertical septa 1007 in females. In some embodiments, the septa 1007 is stretched in a manner that is substantially lasting, durable and/or irreversible. In some embodiments, a septa 1007 is determined to be stretched in a lasting or durable manner such that the septa retains its elongated length for a period that ranges from about 1 hour to about 20 years, from about 2 hours to about 5 years, or from about thirty minutes to about 1 year.

In one embodiment, the septa 1007 (i.e., the stents) are heated to a temperature in the range of from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C. In some embodiments, the temperature range is selected to avoid full coagulation of tissue in the region of the septa 1007. Stretching can be applied to the substantially vertical septa 1007 to increase the length of each septum by a percentage increase that ranges from about 2% to about 70%, or from about 5% to about 50% from the length of the septum prior to stretching. Stretching can be applied simultaneously or after heating within a prescribed temperature range.

In one embodiment, the septa 1007 are heated to a temperature in the range of from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C. and simultaneously and/or subsequent to heating a stretching action is applied to the septa for a period of time necessary to maintain a substantially lasting, durable and/or irreversible extension of the septa 1007. The period of time over which the stretching action can be applied can range from about a tenth of a second to about 24 hours, from about a tenth of a second to about 1 second, from about 30 seconds to about 24 hours, or from about 1 minute to about 1 hour or from about 10 minutes to about 30 minutes.

Over time in a subject's life time the elasticity of their connective tissue (including septa and fascia) can decline for example due to contraction and hardening of connective tissue. The decline in connective tissue can be due, for example, to sclerosis which makes the connective tissue become less flexible or elastic. This loss of elasticity contributes to the cellulite appearance. In other embodiments, referring to FIG. 2A the septa 3007 and/or the fascia 3011 that lie between the muscle 3009 and the dermis 3008 can be stretched in order to elongate the septa 3007 and/or stretch the fascia 3011 to provide “give” to the septa 3007 and/or the fascia 3011 to improve the loss of elasticity associated with cellulite. Stretching the septa 3007 and/or the fascia 3011 can avoid and/or lessen the appearance of cellulite caused by substantially vertical septa 3007 and/or fascia 3011 that has lost elasticity in females.

The septa 3007 and/or the fascia 3011 may be stretched in a manner that is substantially lasting, durable and/or irreversible. In some embodiments, septa 3007 and/or fascia 3011 is determined to be stretched in a lasting or durable manner when the connective tissue (e.g., the septa 3007 and/or the fascia 3011) retains its elongated length for a period that ranges from about 1 hour to about 20 years, from about 2 hours to about 5 years, or from about thirty minutes to about 1 year. The connective tissue (e.g., the septa 3007 and/or the fascia 3011) may be heated to a temperature in the range of from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C. Temperature ranges may be selected to avoid melting and/or to avoid full coagulation of tissue in the region of the septa 3007 and/or the fascia 3011. Stretching can be applied to the connective tissue (i.e., the substantially vertical septa 3007 and the connective tissue 3011) to increase the length of each septum by a percentage increase that ranges from about 2% to about 70%, or from about 5% to about 50% from the length of the connective tissue prior to stretching. Stretching can be applied simultaneously or after heating within a prescribed temperature range.

In one embodiment, the connective tissue (e.g., septa 3007 and/or fascia 3011) are heated to a temperature in the range of from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C. and simultaneously and/or subsequent to heating a stretching action is applied to the septa for a period of time necessary to maintain a substantially lasting, durable and/or irreversible extension of the septa. The period of time over which the stretching action can be applied can range from about a tenth of a second to about 24 hours, from about a tenth of a second to about 1 second, from about 30 seconds to about 24 hours, or from about 1 minute to about 1 hour or from about 10 minutes to about 30 minutes.

The temperature rise in septa and/or the fascia can be implemented in an internal manner and/or an external manner.

Internal Temperature Change Implementation

An internal temperature rise in septa and/or fascia can be implemented internally via an incision in the tissue of a subject and by delivering a probe into the subject's tissue through the incision. The probe can include a tip, for example a tip of a handpiece that emits energy. The tip can be inserted into a subject's tissue in the region of connective tissue to be treated, e.g., septa 1007 and fascia. The clinical endpoint of such treatment is when the connective tissue to be treated (e.g., the septa and/or the fascia) has reached a temperature of from about 45° C. to about 60° C., or from about 44° C. to about 50° C. or more generally a temperature that is less than the temperature at which the connective tissue being treated becomes fully coagulated.

The handpiece tip can emit, for example, a laser or other light emission, ultrasound energy, ohmic resistance that generates energy by simple current, microwave energy, and/or radio frequency energy (e.g., RF energy). These energy sources can have a power level of from about 1 watt to about 100 watts, or from about 10 watts to about 60 watts. The size of the tip can be from about 1 mm to about 6 mm, or from about 1 mm to about 2 mm. Where the energy source is a laser the wavelength can range from about 600 nm to 2300 nm or from about 900 nm to about 1850 nm.

In another embodiment, the handpiece tip can be heated by circulating a fluid such as, for example, hot water inside the tip. The tip temperature can range from about 50° C. to about 100° C.

In another embodiment, a preheated fluid (i.e., a preheated tumescent fluid) or a preheated gas can be injected into an internal region of a subject's body to preheat a volume of the tissue. The preheated fluid is heated up to about 60° C. or from about 40° C. to about 60° C. The temperature of the connective tissue being treated by internal treatment or external treatment can be measured by any of a number of means including, for example, inserting a thermal measurement probe that measures the connective tissue being treated. Thermal probes can be employed to measure and/or enable control of the temperature rise in the connective tissue (e.g., septa and/or fascia) being treated via feedback control such that desired clinical endpoint of connective tissue treatment is when the connective tissue to be treated (e.g., the septa and/or the fascia) has reached a temperature below the temperature of full coagulation for example, from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C. Thus in some embodiments the temperature change of the connective tissue form normal body temperature 37° C. ranges from about 7° C. to about 23° C. In one embodiment, internal heating heats a selected volume and/or region of a subcutaneous tissue. In another embodiment, internal heating selectively heats the fascia and/or the septa 1007 themselves. In another embodiment, internal heating heats a portion of tissue in contact with the septa.

External Temperature Change Implementation

In some embodiments, the temperature rise in connective tissue (e.g., fascia and/or septa) is implemented in an external manner. External heating can heat the whole subcutaneous region, a portion of the subcutaneous region, and/or selectively heat the fascia and/or the septa within the region. In another embodiment, external heating heats a portion of tissue in contact with the fascia and/or the septa. The external temperature rise can be accomplished externally using optical energy with wavelengths of from about 600 nm to 2300 nm or from about 900 nm to about 1850 nm. In another embodiment, microwave energy can be externally applied to the body of a subject; the microwave energy can have a power level suited to raise the temperature of a subcutaneous region and/or the connective tissue (e.g., the fascia and/or the septa) to from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C. or more generally to a temperature that is less than the temperature at which the connective tissue being treated becomes fully coagulated. A suitable power level can range from about 1 watt to about 100 watts or from about 10 watts to about 60 watts. In another embodiment, radio frequency energy (RF energy) can be externally applied to the body of a subject, the RF energy having a power level suited to raise the temperature of a subcutaneous region and/or the targeted connective tissue (e.g., the fascia and/or the septa) to from about 37° C. to about 100° C., or from about 38° C. to about 50° C., or from 45° C. to about 60° C., or from about 44° C. to about 50° C. A suitable power level can range from about 1 watt to about 100 watts or from about 10 watts to about 60 watts. In another embodiment, ultrasound energy (US energy) can be externally applied to the body of a subject, the US energy having a power level suited to raising the temperature of a subcutaneous region and/or the targeted connective tissue (e.g., the fascia and/or the septa) to from about 37° C. to about 100° C., or from about 38° C. to about 50° C., or from 45° C. to about 60° C., or from about 44° C. to about 50° C., for example. A suitable power level can range from about 1 watt to about 100 watts or from about 10 watts to about 60 watts.

In another embodiment, a subcutaneous region and/or the targeted connective tissue (e.g., the fascia and/or the septa) are heated via thermal conduction from the surface of the subject's body (i.e., from the patient's skin) using a hot plate. In some embodiments, one or more of optical energy, microwave energy, RF energy, ultrasound energy, and thermal conduction can be combined with surface cooling to protect the skin (e.g., the epidermis and the dermis) from overheating. Surface cooling methodologies can include contacting the skin surface with a cold gel plate, spray cooling, cold liquid or gas flow cooling, for example. Generally, the cooling medium that contacts the surface of the skin should have a temperature of from about −10° C. to about 20° C., more specifically, a sapphire cooling plate may have a temperature that falls within the range of from about −5° C. to about 10° C.

Methods that can be employed to selectively heat fascia, and/or septa include optical energy employed for selective absorption of subcutaneous tissue (e.g., fat tissue) in preference to skin tissue at suitable wavelength(s). Suitable wavelengths include wavelengths of about 915 nm, about 1208 nm, and about 1715 nm, because these wavelengths provide peak absorption of lipid(s), which is desirable when treating the fat contained (e.g., the lipids) in subcutaneous tissue in preference to skin tissue. Other methods that can be employed include employing microwave energy, US energy, and/or RF energy by selective current through septa due to the relatively low electrical impedance of connective tissue (e.g., fascia and/or septa) compared to surrounding lipid rich tissue.

Stretching of the Septa

The septa and/or the region of tissue including the septa are heated to a temperature in the range of from about 37° C. to about 100° C., or from about 38° C. to about 50° C., or from about 44° C. to about 60° C., or and from about 45° C. to about 50° C. and simultaneously with and/or subsequent to heating a stretching action is applied to the septa for a period of time necessary to maintain a substantially lasting, durable and/or irreversible extension of the septa. The period of time over which the stretching action can be applied can range from about a tenth of a second to about 24 hours, from about a tenth of a second to about 1 second, from about 30 seconds to about 24 hours, or from about 1 minute to about 1 hour or from about 10 minutes to about 30 minutes.

The temperature to which the connective tissue is heated and the time that the connective tissue is exposed to the temperature should be selected to avoid full or complete coagulation of the connective tissue. In one embodiment, the septa and/or region of tissue including the septa are heated to a temperature of about 45° C. or greater and the septa and/or the region of tissue including septa are stretched for a period of time of about 1 minute or greater.

Adipose tissue (i.e., fat tissue) in the region of cellulite has a relatively high heat capacity and a relatively low thermal conductivity compared to skin tissue and has a relatively large volume compared to other types of tissue, for example, skin tissue. Because adipose tissue has a relatively high heat capacity and a relatively large volume after exposure to a temperature increase, adipose tissue in the region of cellulite holds the increased temperature for a period of time that enables stretching to occur over a period of time after the heat source has been applied for example for up to about 1 hour. It is conceivable that heat applied internally (i.e., via heated tumescent solution having a temperature of up to 60° C. and ranging from about 40° C. to about 60° C. can raise the temperature of the septa and/or the fascia to from about 44° C. to about 60° C.) can hold the heat for a period of time that enables internal and/or external stretching to be applied for a period of up to about one hour after injecting the tumescent into the subject's body.

Stretching can be applied to the septa by any of a number of methods or means. For example, in one embodiment, suction is applied to the external surface of a portion of the skin via a vacuum applicator that suctions a portion of the skin thereby placing the skin under negative pressure. In another embodiment, stretching is applied by pushing fluid (e.g., liquid and/or gas) into the tissue in the region to be treated. Optionally, the fluid extends the tissue in the region to be treated by increasing the volume of the region of tissue to be treated by a factor of from about 10% to about 500%, or from about 20% to about 200%, or from about 50% to about 100%. In some embodiments, the fluid is pushed directly into the tissue in the region to be treated. Optionally, in some embodiments, a balloon or bladder in inserted in the region to be treated and is placed, for example, under the skin and/or above the muscle to accept the fluid and to hold the expanded shape for the desired period of time. Fluid can be inserted into the balloon and/or the bladder via injection. Once stretching is completed, the balloon and/or bladder can be deflated by, for example, removing the fluid using the device previously used to inject the fluid into the bladder. In some embodiments, once the balloon and/or the bladder are deflated the balloon and/or the bladder can be removed from the region to be treated. In one embodiment, the balloon and/or the bladder are inserted through an incision made in the subject's body, likewise, the balloon and/or the bladder may be removed via the same incision (e.g., the incision through which the balloon and/or the bladder were placed inside the subject's body).

Referring again to FIG. 1A the fat tissue 1006 includes adipose cells with lipid droplets 1016 a that have extracellular space 1005 between lipid droplets 1016 a. FIG. 1A shows that in tissue the adipose cells with lipid droplets 1016 a are closely packed such that there is a relatively small amount of extracellular space 1005 in the fat tissue.

FIG. 1B shows the region of cellulite tissue discussed in relation to FIG. 1A being stretched. Such stretching of tissue in a region having the appearance of cellulite can be accomplished by external means, such as the devices disclosed in association with FIGS. 4, 5, 6A and 6B or by internal means, for example, by introducing fluid internally to the subject's body.

In one embodiment, FIG. 1B depicts a region of cellulite tissue after tumescent fluid has been injected inside the subject's body 1002 in the region of cellulite.

The quantity of tumescent fluid increases the volume of the region of cellulite in the subject's body by from about 10% to about 500%, or from about 20% to about 200%, or from about 50% to about 100%, or from about 25% to about 75%, or from about 35% to about 50%, or by about 100%. Thus, the tumescent fluid substantially increases the size of the subcutaneous region. Referring to the fat tissue 1006 shown in FIG. 1B, introduction of the tumescent fluid into the subject's body increases the extracellular space 1005 such that the adipose cells with the lipid droplets 1016 a of the fat tissue 1006 are no longer as closely packed as they were prior to introduction of the tumescent fluid (as is depicted in FIG. 1A). Introduction of the tumescent fluid extends and/or stretches the skin (epidermis 1010 and dermis 1008) due to the increase in volume provided by the introduction of tumescent fluid to the tissue. In addition, the introduction of the tumescent fluid increases the length of the septa 1007 a and 1007 b while decreasing the septa thickness. Stretching the tissue region having cellulite by external means would result in a similar increase in the extracellular space 1005 between the lipid droplets 1006 a of the fat tissue 1006 and in a similar lengthening of the septa 1007 a and 1007 b.

In order to maintain the elongated length of the septa 1007 a and 1007 b for a substantially lasting, durable and/or irreversible period of time, the temperature of the septa 1007 a and 1007 b must be increased so that it ranges from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C., Such a temperature increase in the septa can be accomplished by external means such as the devices disclosed in association with FIGS. 4, 5, 6A and 6B.

In some embodiments, the tumescent solution is preheated such that upon injection into the subject's body 1000 the preheated tumescent solution heats the tissue in the region of the septa 1007 to have a temperature of from about 44° C. to about 60° C., or from about 37° C. to about 50° C., or from about 38° C. to about 42° C. The pre-heated tumescent solution has a temperature of up to 60° C. and ranging from about 40° C. to about 60° C. in order to raise the temperature of the septa and/or the fascia to from about 44° C. to about 60° C.).

In other embodiments, the tissue region is stretched (e.g., by external means and/or by unheated tumescent solution) and the septa 1007 are heated by external means such as, for example, by applying ultrasound energy and/or laser or light energy to the region of tissue including the fascia and/or the septa themselves. The temperature of the septa 1007 and the period of time of stretching of the septa 1007 in the presence of the temperature increase are selected to achieve substantially lasting, durable and/or irreversible elongation of the septa 1007 to the length depicted in FIG. 1B. In order to maintain the elongated length of the septa 1007 a and 1007 b for a substantially lasting, durable and/or irreversible period of time, the temperature of the septa 1007 a and 1007 b must be increased so that it ranges from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C. The one or more energy sources employed to increase the connective tissue temperature can have a power level of from about 1 watt to about 100 watts, or from about 10 watts to about 60 watts. Once the connective tissue temperature is increased, the stretching action can be applied to the tissue region for a period of time that can range from about a tenth of a second to about 24 hours, from about a tenth of a second to about 1 second, from about 30 seconds to about 24 hours, or from about 1 minute to about 1 hour or from about 10 minutes to about 30 minutes. For example, the stretching action can be applied to the tissue region by the tumescent solution by maintaining the tumescent solution in the subject's body in the presence of the temperature increase for the desired time period (e.g., the time period necessary to achieve lasting elongation of the septa).

FIG. 1C shows the region of cellulite tissue discussed in relation to FIG. 1B after removal of the stretching force (e.g., removal of an external stretching force such as a vacuum and/or removal of an internal stretching force such as the tumescent solution). The septa 1007 a and 1007 b shown in FIG. 1C are elongated as a result of the stretching and exposure of increased temperature discussed in relation to FIG. 1B. As a result, the septa 1007 a and 1007 b shown in FIG. 1C enjoy a decrease of tension in the substantially vertical septa 1007 as compared to the septa 1007 shown in FIG. 1A prior to exposure to stretching and temperature increase. Exposing the septa 1007 to stretching and increased temperature provides an improved appearance of cellulite on the external surface 1004 of the female subject's body 1000.

Referring now to FIG. 2A the fat tissue 3006 includes adipose cells with lipid droplets 3016 a that have extracellular space 3005 between lipid droplets 3016 a. FIG. 2A shows that in tissue the adipose cells with lipid droplets 3016 a are closely packed such that there is a relatively small amount of extracellular space 3005 in the fat tissue 3006.

FIG. 2B shows the region of cellulite tissue discussed in relation to FIG. 2A after the region of cellulite tissue has been stretched (e.g., by external means or by internal means such as injection of tumescent fluid inside the subject's body 3002 in the region of cellulite).

Still referring to FIG. 2B, in an embodiment where the tumescent fluid is injected to increase the volume of the region to be treated in the subject's body the tumescent fluid increased the volume of the region of tissue to be treated by a factor of from about 10% to about 500%, or from about 20% to about 200%, or from about 50% to about 100%, or from about 25% to about 75%, or from about 35% to about 50%, or by about 100%. Thus, the tumescent fluid substantially increases the size of the subcutaneous region. Referring to the fat tissue 3006 shown in FIG. 1B, introduction of the tumescent fluid into the subject's body increases the extracellular space 3005 such that the adipose cells with the lipid droplets 3016 a of the fat tissue 3006 are no longer as closely packed as they were prior to introduction of the tumescent fluid (as is depicted in FIG. 2A).

Introduction of the tumescent fluid extends and/or stretches the skin (epidermis 3010 and dermis 3008) due to the increase in volume provided by the introduction of tumescent fluid to the tissue. In addition, the introduction of the tumescent fluid increases the length of the septa 3007 a, 3007 b, 3007 d, and 3007 e, which increases the length of the septa 3007 and increases the length of the fascia 3011 while decreasing the septa 3007 thickness and decreasing the fascia 3011 thickness. Stretching the tissue region having cellulite by external means would result in a similar increase in the extracellular space 3005 between the lipid droplets 3016 a of the fat tissue 3006, a similar lengthening of the septa 3007 a, 3007 b. 3007 d, and 3007 e and in a similar lengthening of the fascia 3011 as described when stretching was accomplished by introduction of the tumescent fluid in the subject's body.

Referring still to FIG. 2B, in order to maintain the elongated length of the septa and/or the fascia for a substantially lasting, durable and/or irreversible period of time, the temperature of the septa 3007 and/or the fascia 3011 must be increased so that it ranges from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C. In some embodiments, tumescent solution is preheated such that the preheated tumescent solution has a temperature of up to 60° C. and a temperature that ranges from about 40° C. to about 60° C. such that upon injection into the subject's body 3000 the preheated tumescent solution heats the tissue in the region of the septa 3007 and/or the tissue in the region of the fascia 3011 to have a temperature of from about 44° C. to about 60° C., or from about 37° C. to about 50° C., or from about 38° C. to about 42° C.

In other embodiments, the tissue region is stretched (e.g., by external means and/or by unheated tumescent solution) and the connective tissue (e.g., the septa 3007 and/or the fascia 3011) are heated by an energy source provided by external means such as, for example, by applying ultrasound energy and/or laser or light energy to the region of tissue including the septa, the septa themselves, the region of tissue including the fascia and/or the fascia itself. The temperature of the septa 3007 and/or the fascia 3011 and the period of time of stretching of the septa 3007 and/or the fascia 3011 are selected to achieve substantially lasting, durable and/or irreversible elongation of the connective tissue (e.g., the septa 3007 and/or the fascia 3011) to the length depicted in FIG. 2B. The connective tissue to be treated (e.g., the septa and/or the fascia) is treated to reach a temperature below the temperature of full coagulation for example, from about 37° C. to about 100° C., or from about 38° C. to about 60° C., from about 44° C. to about 60° C., or from about 45° C. to about 50° C.

Once the connective tissue temperature is increased in the presence of a stretching force the temperature increase is held for a period of time that can range from about a tenth of a second to about 24 hours, from about a tenth of a second to about 1 second, from about 30 seconds to about 24 hours, or from about 1 minute to about 1 hour, or from about 10 minutes to about 30 minutes. The external energy sources employed to increase the connective tissue temperature can have a power level of from about 1 watt to about 100 watts, or from about 10 watts to about 60 watts.

FIG. 2C shows the region of cellulite tissue discussed in relation to FIGS. 2A and 2B after removal of the stretching force (e.g., removal of an external stretching force such as a vacuum and/or removal of an internal stretching force such as the tumescent solution). FIG. 2C shows that the septa 3007 and fascia 3011 are elongated as a result of the stretching and exposure to the increased temperature discussed in relation to FIG. 2B. As a result, the septa 3007 and fascia 3011 shown in FIG. 2C enjoy a decrease of tension in the substantially vertical septa 3007 as compared to the septa 3007 shown in FIG. 2A prior to exposure to stretching and temperature increase. Likewise, exposure to stretching and increased temperature reduces the tension in the fascia 3011 by, for example, elongating at least a portion of the fascia 3011. Exposing the septa 3007 and the fascia 3011 to stretching and increased temperature provides an improved appearance of cellulite on the external surface 3004 of the female subject's body 3000.

In some embodiments, in order to avoid the muscle (e.g., the muscle underlying the fascia and/or the septa to be treated) from moving and/or pulling as a result of exposure to a stretching mechanism the practitioner can instruct the subject to flex their muscle in the treatment region. Flexing the muscle can aid in fixing the muscle and help prevent the muscle from being suctioned as well. In one embodiment, a flexing action can be accomplished in a desired muscle by using electrical conduction to fixate the muscle during application of an external stretching technique (e.g., by applying electrical muscle stimulation to the muscle beneath the area being treated to contract the muscle). The muscle can be stretched prior to, simultaneous with and/or subsequent with use of a stretching mechanism (e.g., an external stretching mechanism such as an external vacuum).

In one embodiment, during stretching, ultrasound energy is delivered to the septa. Ultrasound energy can support the substantially permanent expansion (i.e., stretching) of the septa by creating cavitation bubbles in the fiber of the septa. Cavitation bubbles in the fiber of the septa can weaken the septa to promote stretching. Ultrasound energy can be applied to generate one or more acoustic shock wave(s) that propagate through the dermis and the subcutaneous region to reach the septa. Ultrasound energy can be applied to generate oscillation of septa and oscillation of septa can support lasting (e.g., irreversible) elongation of the septa. In some embodiments the ultrasound frequency is selected to match or to substantially match the resonance frequency of oscillation of the septa and/or of the septa and any subcomponents that the septa contain. The resonance frequency of oscillation can range from about 10 MHz to about 1 GHz. In other embodiments, the ultrasound frequency is selected to match or to substantially match harmonics of the resonance frequency of the septa and any subcomponents that the septa contain. The harmonics of the resonance frequency can range from about 20 MHz to about 2 GHz.

In one embodiment, stretching is combined with vibration (e.g., vacuum is externally applied to the subject's skin together with a vibration action). In another embodiment, stretching is combined with torquing (e.g., twisting) of tissue, for example, vacuum is externally applied to the subject's skin together with a twisting action. The twisting action can have a torque that ranges from about 0.3 N-m to about 3 N-m. The vibration action can have a frequency that ranges from about 5 Hz to about 200 Hz.

Referring again to FIGS. 1A and 2A, the practitioner can be visually guided by the dimples 1003, 3003 on the subject's body 1000, 3000 to determine the region for treatment in an internal portion of the body 1002, 3002. In one embodiment, a handpiece including an aiming beam provides a visual aid to assist treatment of the subject. For example, where cellulite is being treated, a portion of the handpiece is inserted into the internal portion of the subject's body 1000, 3000. The practitioner can line the aiming beam of the handpiece in line with a visible dimple 1003, 3003 indicative of cellulite present on the external position of the body 1004, 3004. Once aligned with the visible dimple, with the aid of the aiming beam, the waveguide is positioned to treat the septa 1007 (e.g., to heat and/or stretch the septa) in the region of the visible dimple 1003. Alternatively, referring to FIG. 2A the waveguide is positioned to treat the septa 3007 and/or the fascia 3011 (e.g., to heat and/or stretch the septa and/or the fascia) in the region of the visible dimple 3003. In another embodiment, referring now to FIG. 1A, an aiming beam can be employed to locate individual septa (e.g., 1007 a) in a region of skin. The aiming beam can make visible to the practitioner the presence of the septa 1007 in the subject's body 1000. Once the septa 1007 is made visible to the practitioner the septa 1007 and/or the region of the septa 1007 may be heated to a suitable temperature and simultaneous with or subsequent to heating the septa 1007 may be stretched by, for example, applying vacuum to the septa 1007.

In one embodiment, the treatment is combined with other visualization techniques that enable visualization of the connective tissue structure (e.g., the septa and/or fascia tissue structure) to control the location of the applicator and/or the results of the treatment. Suitable visualization techniques can include, for example, use of diagnostic ultrasound as a visualization technique.

In one embodiment, a cannula having a diameter that ranges from about 0.5 mm to about 8 mm, or about 2 mm is inserted into the body of a subject through an incision. The cannula includes an energy source (e.g., a light source) that heats the region of tissue into which the cannula has been inserted. The cannula and the energy source heat the region of tissue, which includes septa to a temperature of about 45° C. A source of vacuum is employed to stretch the connective tissue (e.g., the septa and/or the fascia tissue). The temperature of about 45° C. is employed because it avoids coagulation and it avoids melting of the adipose cells in the region of the connective tissue (e.g., the septa and/or the fascia tissue).

The desired level of connective tissue elongation may be confirmed via visual confirmation that the appearance of cellulite is reduced and/or eliminated. Where the treatment is non invasive (e.g., external treatment) the visual confirmation may be made just after treatment. Where the treatment is invasive (i.e., internal treatment with a cannula) the visual confirmation may likewise be made after the treatment is completed once the cannula is removed from the subject's body. Where the invasive treatment includes a fluid for example a liquid such as water or tumescent or a gas injected into the subject's body, the visual confirmation may be made upon release of the fluid (e.g., the tumescent or the gas). In some embodiments, the connective tissue that is elongated (e.g., the fascia and/or the septa) is increased in length by from about 5% to about 50%.

FIG. 4 shows a device 4000 for externally heating a region of tissue, including septa, and for applying vacuum and/or suction to the region to stretch the heated septa. More specifically, the device includes a first vacuum 4020, one or more energy source 4012, a cooling plate 4014, and a second vacuum 4030. The device ensures good contact of the energy source 4012 by applying a first vacuum 4020 to a region of tissue prior to exposing the tissue to one or more energy source 4012 and, after heating of the tissue region is complete, a second vacuum 4030 is applied to the tissue region. In this way, the septa contained in the tissue region may be heated via the energy source 4012 and then stretched by a vacuum (e.g., 4020 or 4030). The vacuum pressure can range from about −500 mmHg to about −5 mmHg, or from about −350 mmHg to about −50 mmHg. The one or more energy source(s) 4012 may include one or more of the energy sources described herein (e.g., ultrasound, RF energy, light energy etc.). The power level of the energy source can range from about 1 watt to about 100 watts or from about 10 watts to about 60 watts. Where the energy source is light based the wavelength can range from about 600 nm to 2300 nm, or from about 900 nm to about 1850 nm. The cooling plate may include or incorporate any suitable cooling means known to the skilled person including, but not limited to, any of the cooling means disclosed herein. Generally, the cooling plate can have a temperature range of from about −5° C. to about 20° C. more specifically a sapphire cooling plate may have a temperature range of from about −5° C. to about 10° C. In this way the septa in the tissue region stretched in a manner that is substantially lasting, durable and/or irreversible. The device 4000 is employed on an external surface of the subject's body to improve the appearance of cellulite caused by substantially vertical and/or substantially tight septa and/or fascia in the tissue region.

FIG. 5 shows a device for externally heating a region of tissue including septa 5007 a-5007 e disposed between skin tissue 5011 and muscle 5009. The device includes an energy source 5012 and adjacent the energy source 5012 are two cooling plates 5014 and 5016 that surround a cooling liquid 5015. The device also includes a source of vacuum 5099. The vacuum pressure can range from about −500 mmHg to about −5 mmHg, or from about −350 mmHg to about −50 mmHg. The vacuum source 5099 pulls the subject's tissue between the cooling plates 5014. The configuration of the device of FIG. 5 can create a “pinch” or a “fold” of tissue that is held adjacent the cooling plate 5014 of the device.

The cooling plate can be an optically transparent dielectric material. Generally, the cooling plate can have a temperature range of from about −5° C. to about 20° C. or the cooling plate can have a temperature range of from about −5° C. to about 10° C. The cooling plate may be made from sapphire. Cooling the plate to the temperature range of −5° C. to about 20° C. or from about −5° C. to about 10° C. allows deep heating by light without damaging the epidermis. Such cooling done in parallel with light delivery can allow irradiation times that can range from about a tenth of a second to about 24 hours, from about a tenth of a second to about 1 second, from about 30 seconds to about 24 hours, or from about 1 minute to about 1 hour or from about 10 minutes to about 30 minutes. In some embodiments, the treatment power density for wavelengths in the near-infrared wavelength range is on the order of from about 1 W/cm² to about 100 W/cm², or from about 1 W/cm² to about 10 W/cm². Heating and cooling may be cycled, cycling of heating and cooling can promote a substantially uniform temperature change in the area of tissue treatment. Thermocycling of heating and cooling can contribute to lasting elongation of connective tissue being treated (e.g., septa tissue and/or fascia tissue). Cycling of heating and cooling can be employed so that heating via the energy source and cooling have intensities that are matched to one another (e.g., as the energy for heating is increased the cooling temperature is decreased and as the energy for heating is decreased the cooling temperature is increased).

The energy source 5012 increases the temperature of the tissue region including the septa 5007. FIG. 5 depicts the energy source 5012 of the device applying energy to the tissue region, more specifically, to the septa 5007 c in the tissue region while vacuum 5099 stretches the septa 5007 c to which the energy source is being applied. In this way the septa 5007 c is stretched in a manner that is substantially lasting, durable and/or irreversible. The vacuum 5099 may be modulated (e.g., the amount of suction may be alternated and/or modulated) to enhance stretching of the skin.

The device shown in FIG. 5 is employed on an external surface of the subject's body to improve the appearance of cellulite caused by substantially vertical and/or substantially tight septa 5007 and or by fascia (not shown in FIG. 5).

The power level of the energy source can range from about 1 watt to about 100 watts or from about 10 watts to about 60 watts. Where the energy source is a light based (e.g., laser) the wavelength can range from about 600 nm to 2300 nm or from about 900 nm to about 1850 nm.

The energy source 5012 can feature different optical schemes (i.e. with or without optical fibers) that can be used to irradiate the skin fold. In one embodiment, diode laser bars together with suitable optics are mounted in the device and create one or more irradiation areas (each having an irradiation area on the order of from about 5×20 mm², or from about 25×200 mm², or from about 15×70 mm²) that are adjacent to the skin fold. In one embodiment, two diode laser bars (each having an irradiation area on the order of 15×70 mm²) are located in the device each on one side of a skin fold. In another embodiment, diode light is delivered via beam-shaping optics through two cooled sapphire windows with one window located on each side of the skin fold (the cooled sapphire windows are on the order of 15×70 mm²).

Referring still to FIG. 5 in an embodiment where the energy source 5012 includes ultrasound energy (e.g., acoustic energy), which may be applied to the region of tissue being treated at the same time as the stretching force is applied to the region of tissue being treated. In some embodiments, lasting stretching is enhanced by the acoustic energy whereby the fascia, septa, and/or all of the connective tissue in the treatment region vibrates in the presence of the acoustic energy.

More specifically, the device applies vacuum 5099 to a region of tissue to be treated (e.g., to a pinch of tissue) at least a portion of a side of the pinch of tissue is exposed to ultrasound energy (e.g., acoustic energy). Ultrasound energy (e.g., acoustic energy) may be employed as the only energy source 5012 and/or acoustic energy may be employed in combination with other sources of energy, such as, for example, light energy. Acoustic energy can provide mechanical vibration when the acoustic energy has a frequency range of from about 10 Hz to about 10 kHz. Acoustic energy can produce cavitation in the subcutaneous tissue when it has a frequency range of from about 5 kHz up to 1 MHz. Acoustic energy can achieve a heating effect when it has a frequency range from about 0.5 MHz to about 1 GHz. In one embodiment, a cooling element (e.g., a cooling plate 5014, 5016) contacts the skin surface while the acoustic and/or light energy is being applied to the skin surface. In one embodiment, the cooling element cools the skin surface down to, for example, 0° C. Suitable cooling elements may be made from, for example, cooled sapphire. Any suitable cooling mechanism may be employed such as, for example, a peltier cooler.

In one embodiment, referring to FIGS. 6A and 6B, the device has an outer housing 6030 that may be structurally flexible (made, for example, from silicone rubber), which allows the device to accommodate varying skin fold thicknesses. Alternatively, the outer housing 6030 can be made from a rigid material. In such a device the energy source(s) 6012 (e.g., optical component(s)) may be located on only a portion of the device. For example, in one embodiment, the device features two separate sapphire treatment windows 6012 that are separated from one another by the material of the outer housing 6030 (e.g., the flexible material of the outer housing) and vacuum 6099 is pulled through the device. A region of tissue to be treated 6001 includes skin and subcutaneous tissue, and during treatment within the recess 6050 of the device the region of tissue to be treated 6001 can assume the shape of a pinch or a fold when the region to be treated 6001 is pulled into the recess 6050 within the device. During use of the device, additional mechanical pressure can be applied to the energy source(s) 6012 (e.g., two sapphire treatment windows) to ensure good thermal/optical contact and to displace blood in the region of tissue to be treated. For example, in one embodiment, mechanical pressure such as a pushing or a squeezing force may be applied to the sapphire treatment windows 6012 that are disposed on or are adjacent to the flexible material of the outer housing 6030. Such a mechanical force may be employed on the device alternatively or in addition to application of a vacuum pressure 6099. In some embodiments, the skin fold is compressed and expanded (e.g., repeatedly compressed and expanded) to improve blood circulation during treatment of the tissue held within the device recess 6050 during treatment. The energy source 6012 may include one or more cooling element(s) employed to cool the region of skin tissue to be treated, suitable cooling elements can include the cooling plates disclosed in relation to FIG. 5. FIGS. 6A and 6B show the energy source(s) 6012 on the external surface of the outer housing 6030, however, suitable devices can include energy source(s) on the internal surface of the outer housing such that the energy source(s) directly contact the region to be treated 6001 when it enter the recess 6050 therein.

Optionally, the device includes vibration and/or massage. In one embodiment, massage is used in a twisting motion and/or a shearing motion provided in a direction parallel to the skin fold. In one embodiment, contact sensors are disposed on within the portion of the device in contact with the skin tissue and the contact sensors can be employed to ensure the skin being treated (e.g., a skin fold) stays in contact with the sapphire cooling windows. In one embodiment, a skin color sensor is employed to automatically adjust the power of the energy source (e.g., the diode laser) based on a measurement of the skin melanin optical density. In some embodiments, a temperature sensor is embedded in the device (e.g., in the sapphire window) and the temperature sensor can be employed to ensure that the skin does not overheat during treatment. The device may employ photon recycling to enhance heating of the skin fold by redirecting photons scattered out of the skin fold back into the skin fold. In other embodiments, one or more septa may be stretched by any of the means described herein and all or a portion of one or more septa may be cut and/or may fraction thereby to diminish and/or eliminate the tension in the septa that can cause the cellulite appearance. The one or more septa may be cut by any of the internal or external means described herein. Alternatively, the one or more septa may be cut by employing surgical tools known for cutting such as, for example, knives, scalpels, and/or cauterization devices.

The techniques described herein for improvement of cellulite appearance may be employed to treat the cellulite of subjects ranging in age from relatively young subjects that have just begun to exhibit the cellulite appearance (e.g., teenagers) or relatively older subject's including post menopausal and/or elderly female subjects. 

1. A method of improving the appearance of cellulite, the method comprising: applying a stretching force to at least one of a septa tissue and a fascia tissue that is adjacent to fat tissue beneath a region of a subject's skin having the appearance of cellulite; and heating at least one of the septa tissue and the fascia tissue for a period of time and at a temperature sufficient to achieve lasting elongation of at least one of the septa tissue and the fascia tissue upon release of the stretching force. 2-14. (canceled) 